Effects of noradrenergic denervation on L-DOPA-induced dyskinesia and its treatment by α- and β-adrenergic receptor antagonists in hemiparkinsonian rats

While L-3,4-dihydroxyphenylalanine (L-DOPA) remains the standard treatment for Parkinson’s disease (PD), long-term efficacy is often compromised by L-DOPA-induced dyskinesia (LID). Recent research suggests that targeting the noradrenergic (NE) system may provide relief from both PD and LID, however,...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Barnum, Christopher J., Bhide, Nirmal, Lindenbach, David, Surrena, Margaret A., Goldenberg, Adam A., Tignor, Stefanie, Klioueva, Anna, Walters, Hannah, Bishop, Christopher
Formato: Artigo
Idioma:Inglês
Publicado em: 2011
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3242909/
https://ncbi.nlm.nih.gov/pubmed/21978941
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.pbb.2011.09.009
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados